LCLingli Cui

Lingli Cui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lingli Cui has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Liang Zhang

    Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of China

    4 shared publications
  • Qian Zhu

    Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China

    4 shared publications
  • Shen Liu

    Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of China

    3 shared publications
  • Danxu Ma

    Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

    2 shared publications
  • Fu-Shan Xue

    Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China

    2 shared publications
  • Xiuliang Li

    Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Comparing Efficacy of Oxycodone versus Sufentanil for Postoperative Recovery in Patients Receiving Bilateral Modified Thoracoabdominal Nerves Block Through Perichondrial Approach (M-TAPA) Following Laparoscopic Radical Distal Gastrectomy: A Study Protocol for a Prospective, Blinded, Randomized Controlled Trial

    by Jiaqi Tong, Lingli Cui, Yueting Wei, Xinyan Zhu, Danxu Ma

    Introduction: While laparoscopic radical distal gastrectomy (LRDG) has been widely adopted for its minimally invasive benefits in the treatment of gastric cancer, acute postoperative pain, comprising both somatic incisional pain and visceral discomfort, remains a clinical challenge that can affect patients’ perioperative comfort and the rehabilitation process. Consequently, optimizing postoperative analgesic strategies remains essential for enhanced recovery. The modified thoracoabdominal nerves block through a perichondrial approach (M-TAPA) has been introduced as an emerging regional analgesic technique for upper abdominal incisions. In the regard of effective management of visceral pain, oxycodone is a unique agonist at κ-opioid receptors and potentially influences inhibiting visceral nociceptive transmission better than sufentanil. Therefore, this study aims to evaluate whether the combination of M-TAPA with oxycodone-based patient-controlled intravenous analgesia (PCIA) is more effective to provide analgesia efficacy and facilitate gastrointestinal recovery compared to a sufentanil-based analgesic regimen. Methods/Analysis: This single-center, prospective, double-blind, randomized controlled trial will enroll 96 patients scheduled for elective laparoscopic radical distal gastrectomy. Eligible patients will be randomly assigned at a 1:1 ratio to receive either Oxycodone PCIA (Group O) or Sufentanil PCIA (Group S). Both groups will receive bilateral ultrasound-guided M-TAPA before surgical incision. The primary outcome is the Quality of Recovery-15 (QoR-15) score assessed at 24 hours postoperatively. Secondary outcomes include static and dynamic numeric rating scale (NRS) pain scores, cumulative opioid consumption (converted to intravenous morphine equivalents), clinical recovery milestones, and the incidence of adverse events such as postoperative nausea and vomiting (PONV) and respiratory depression. Ethics and Dissemination: This trial was approved by the Ethics Committee of Beijing Friendship Hospital, Capital Medical University on August 28, 2025. The trial started recruiting patients after being registered on the Chinese Clinical Trial Registry. Trial Registration Number: ChiCTR2600119394.

  • Open Access

    The Analgesic Efficacy of Ultrasound-Guided Transversus Abdominis Plane Block for Laparoscopic Living Donor Hepatectomy: A Randomized Controlled Study

    by Shen Liu, Yuxuan Yang, Lin Wei, Liang Zhang, Xiuliang Li, Xiaofang Hao, Lingli Cui

    Purpose: The transversus abdominis plane (TAP) block provides effective postoperative analgesia for abdominal surgeries. However, its efficacy in laparoscopic living donor hepatectomy (LLDH) remains uncertain. This study aimed to assess the impact of ultrasound-guided TAP block on postoperative analgesia and recovery quality in living liver donors undergoing LLDH. Patients and Methods: In this prospective, randomized, double-blind controlled trial, eighty patients scheduled for LLDH were randomly allocated 1:1 to receive ultrasound-guided bilateral single-injection TAP block (Group T) or local incisional infiltration (Group C). The primary outcome was total opioid consumption within 24 hours postoperatively. Secondary outcomes were visual analogue scale (VAS) pain scores, opioid consumption within 48h postoperatively, Quality of Recovery-15 (QoR-15) scores, time to first flatus and ambulation, length of hospital stay (LOS), postoperative liver function, opioid related adverse reactions, and puncture-related complications. Results: The total opioid consumption within 24 hours postoperatively as the primary outcome was significantly lower in group T compared to group C (42 [38.5, 54] mg vs. 62 [52, 68] mg, P < 0.001), and this significant difference was also present at 48 hours postoperatively (98 [84.5, 104.5] mg vs. 112 [102, 133] mg, P < 0.001). The VAS scores at rest and movement were also lower in Group T at 2h after surgery (P < 0.01). Moreover, patients in Group T had earlier first postoperative flatus (P = 0.012). No significant differences between groups were observed in other secondary outcomes. Conclusion: Ultrasound-guided TAP block can reduce postoperative opioid consumption, alleviate early postoperative pain without increasing adverse events in living donors undergoing the LLDH.

  • Open Access

    Low-Dose Dexmedetomidine Reduces Median Effective Doses of Propofol Required for Successful Gastroscope Insertion: A Prospective Randomized Controlled Dose-Finding Trial

    by Qian Zhu, Pei-Pei Hao, Ling-Li Cui, Fu-Kun Liu, Fu-Shan Xue

    Purpose: Patients undergoing painless gastrointestinal endoscopy (GIE) typically receive propofol-based sedation. However, the exact dose of propofol when combined with low-dose dexmedetomidine for this procedure remains unclear. The objective of this study was to determine and compare the median effective doses (ED50, the doses required for successful gastroscope insertion in 50% of the subjects) of propofol when used with low-dose dexmedetomidine (0.3 μg/kg) premedication versus propofol alone during painless GIE. Patients and Methods: Adult outpatients aged 18 to 65 years scheduled for GIE were enrolled. Participants were randomized to receive either 0.9% saline (Group S) or 0.3 μg/kg of dexmedetomidine (Group D) intravenously over 5 min before induction with propofol. Using modified Dixon’s up-and-down method (MDUDM), the initial induction dose of propofol was 1.5 mg/kg, adjusted in a step size of 0.1 mg/kg. ED50 of propofol required for successful endoscope insertion was calculated by averaging the midpoints of all sequential crossovers. Using isotonic regression analysis, ED50 and ED95 (the effective doses required for successful gastroscope insertion in 95% of the subjects) were then extrapolated. All adverse events during painless GIE were recorded. Results: Thirty patients were enrolled per group. Using MDUDM, the ED50 of propofol for successful gastroscope insertion was significantly lower in Group D (1.48 ± 0.10 mg/kg) than in Group S (1.82 ± 0.16 mg/kg; P < 0.001). The ED50 and ED95 of propofol were extrapolated to 1.80 mg/kg (83% confidence interval [CI], 1.649– 1.882) and 2.10 mg/kg (83% CI, 2.081– 2.124) for Group S, respectively, using isotonic regression analysis. These values were significantly lower in Group D, at 1.40 mg/kg (83% CI, 1.297– 1.452) and 1.70 mg/kg (83% CI, 1.667– 1.753). Conclusion: Premedication with low-dose dexmedetomidine (0.3 μg/kg) significantly reduces the median effective doses of propofol required for successful gastroscope insertion during painless GIE.


  • Open Access

    Dexmedetomidine Cannot Attenuate Liver Injury and Improve Outcomes Following Laparoscopic Living Donor Hepatectomy: A Randomised Controlled Trial

    by Ling-Li Cui, Liang Zhang, Shen Liu, Qian Zhu, Fu-Shan Xue

    Purpose: To determine the effects of intraoperative dexmedetomidine (DEX) administration on postoperative ischaemia/reperfusion injury (HIRI) and clinical outcomes of patients undergoing the laparoscopic living donor hepatectomy (LLDH). Patients and Methods: Fifty-five patients who underwent the LLDH were randomly assigned to the DEX or control group. The DEX group received an intravenous infusion of DEX with an bolus dose of 1 μg/kg for 15 min before anaesthesia induction, followed by a continuous infusion at a rate of 0.4 μg/kg/h until the portal branch was disconnected. The control group was given an intravenous infusion of 0.9% saline at same volume and rate. The primary outcome was peak serum aspartate aminotransferase (AST) level during the first 72 h postoperatively. The secondary outcomes included other variables of postoperative liver and kidney function, intraoperative hemodynamic changes, postoperative recovery outcomes and the occurrence of complications. Results: The peak serum AST level during the first 72 h postoperatively was not significantly different between groups (DEX vs control: 288 [194– 466] vs 324 [194– 437] IU/L; difference, − 1.2 IU/L; 95% CI, − 86.9 to 88.0; P=0.973). The intraoperative mean artery pressure was not significantly different, but intraoperative heart rate was significantly decreased in the DEX group. There were no significant differences between groups in other secondary outcomes. Conclusion: This study demonstrates that intraoperative DEX administration at the studied dosage regimens cannot attenuate postoperative HIRI and does not improve clinical outcomes in patients undergoing the LLDH. Clinical Trial Registration: www.chictr.org.cn, ChiCTR2000040629.


  • Open Access

    Effect of Low Thoracic Paravertebral Block via the Arcuate Ligament Under Direct Visualization on the Quality of Postoperative Recovery After Laparoscopic Donor Nephrectomy for Living-Donor Kidney Transplantation: Study Protocol for a Prospective, Blinded, Randomized Controlled Clinical Trial

    by Lingli Cui, Yichen Zhu, Shen Liu, Liang Zhang, Qian Zhu, Yun Wang, Danxu Ma

    Introduction: Laparoscopic donor nephrectomy (LDN) is the standard procedure for donor nephrectomy for living kidney transplantation. Compared with traditional open surgery, the laparoscopic techniques have been developed to significantly reduce postoperative pain and accelerate postoperative recovery; however, most donors still experience more than moderate pain after surgery. Ensuring maximum perioperative safety and postoperative pain control for donors remains a top priority for LDN. Our group reported a novel blockade technique that allows local anesthetic to be injected directly to reach the low thoracic paravertebral space under direct laparoscopic observation via the arcuate ligament to achieve somatic and visceral pain analgesia; this technique has been successfully applied to patients undergoing retroperitoneal laparoscopic nephrectomy. We hypothesized that compared with the transversus abdominis plane (TAP) block, low thoracic paravertebral block (TPVB) via the arcuate ligament under direct vision would reduce the consumption of postoperative opioids and improve the quality of postoperative recovery of donors after LDN. Methods/Analysis: This study is a prospective blind, randomized, controlled clinical trial with a concealed allocation of donors scheduled to undergo elective LDN 1:1 to receive either a low TPVB via the arcuate ligament under direct vision or a TAP block. This study will recruit a total of 82 living kidney donors. The primary outcome is the 15-item recovery quality scale (QoR-15) score at 24 hours after surgery. Ethics and Dissemination: This trial was approved by the Ethics Committee of Beijing Friendship Hospital, Capital Medical University. This trial study protocol was approved on 30 November 2024. The trial started recruiting patients after being registered on the Chinese Clinical Trial Registry. Trial Registration Number: ChiCTR2400094612.

  • Open Access

    Young, Healthy, Underweight Women Require Higher Effective Doses of Propofol for Successful Gastroscope Insertion: a Dose-Finding Study Using Dixon’s Up-and-Down Method

    by Qian Zhu, Lingli Cui, Xinyue Li, Qipei Li, Yun Wang

    Purpose: The number of young women undergoing painless gastroscopy is rising annually. However, the lack of studies on the effective doses of propofol sedation for young, underweight women, presents a clinical challenge. Our study aimed to determine and compare the effective doses of propofol required for successful gastroscope insertion in normal-weight and underweight young women. Patients and Methods: Chinese women aged 18– 35 years who were of normal weight (18.5 ≤ body mass index (BMI) < 25 kg/m²) or underweight (BMI < 18.5 kg/m²) and were undergoing painless gastroscopy were included. The initial induction dose of propofol was 2.0 mg/kg, and subsequent doses were adjusted using the modified Dixon’s up-and-down method (step size: 0.1 mg/kg). The 50% and 95% effective dose of propofol (ED50 and ED95), defined as the doses required for successful gastroscope insertion in 50% and 95% of patients, respectively, were determined using the modified Dixon’s up-and-down method and isotonic regression analysis. All adverse events were documented. Results: Thirty patients were included in each group. The modified Dixon’s up-and-down method was used, and the ED50 of propofol was found to be significantly higher in patients in the underweight group (2.72 ± 0.23 mg/kg) than those in the normal-weight group (2.03 ± 0.13 mg/kg) (P < 0.001). The ED50 and ED95 in the normal-weight group extrapolated using isotonic regression analysis were 2.00 (83% confidence interval [CI], 1.900– 2.100) mg/kg and 2.30 (83% CI, 2.300– 2.400) mg/kg, respectively. In the underweight group, these values increased to 2.80 (83% CI, 2.700– 2.900) mg/kg and 3.00 (83% CI, 3.000– 3.100) mg/kg, respectively. The nonoverlapping CIs indicated significant differences between patients in the normal-weight and underweight groups. Conclusion: Young, healthy, underweight women require higher effective doses of propofol for deep sedation for successful gastroscope insertion compared with young, healthy, normal-weight women.


  • Open Access

    Clinical Trial Study Protocol: A Prospective Blinded, Randomized, Controlled Clinical Trial Protocol to Assess the Efficacy of Ultrasound-Guided Transversus Abdominis Plane Block on Postoperative Analgesia and Recovery Quality in Laparoscopic Donor Hepatectomy

    by Shen Liu, Bijia Song, Liang Zhang, Xiuliang Li, Lingli Cui

    Introduction: Liver transplantation is considered an effective treatment for end-stage liver disease. Laparoscopic donor hepatectomy (LDH) has become a new standard procedure. And it is important to minimize the pain of the donor. Good postoperative analgesia can reduce the occurrence of postoperative complications and promote the early recovery of the donor. Ultrasound-guided transversus abdominis plane (TAP) block can provide effective analgesia for liver donors and reduce postoperative opioid consumption. This study aims to use ultrasound-guided TAP block for LDH to improve postoperative analgesia for donors while reducing opioid consumption and improving patient rehabilitation quality. Methods/Analysis: This study is a prospective blinded, randomized, controlled clinical trial with a concealed allocation of patients (living liver donors) scheduled to receive laparoscopic partial hepatectomy 1:1 to receive local infiltration anesthesia or TAP block. This study will recruit a total of 80 patients. The primary outcome is the dosage of opioids within 24 hours after surgery. Ethics and Dissemination: This trial has been approved by the Institutional Review Board of Beijing Friendship Hospital of China Capital University. This trial study protocol was approved on 8 May 2023. The trial will start recruiting patients after being registered on the Chinese Clinical Trial Registry. Trial Registration Number: ChiCTR2300071694.